GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Fuse Medical Inc (OTCPK:FZMD) » Definitions » Debt-to-EBITDA

Fuse Medical (Fuse Medical) Debt-to-EBITDA : 1.38 (As of Jun. 2023)


View and export this data going back to . Start your Free Trial

What is Fuse Medical Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Fuse Medical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $2.22 Mil. Fuse Medical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.00 Mil. Fuse Medical's annualized EBITDA for the quarter that ended in Jun. 2023 was $1.61 Mil. Fuse Medical's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 was 1.38.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Fuse Medical's Debt-to-EBITDA or its related term are showing as below:

FZMD' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.95   Med: 0.11   Max: 3.89
Current: 0.56

During the past 13 years, the highest Debt-to-EBITDA Ratio of Fuse Medical was 3.89. The lowest was -1.95. And the median was 0.11.

FZMD's Debt-to-EBITDA is ranked better than
66.28% of 430 companies
in the Medical Devices & Instruments industry
Industry Median: 1.225 vs FZMD: 0.56

Fuse Medical Debt-to-EBITDA Historical Data

The historical data trend for Fuse Medical's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fuse Medical Debt-to-EBITDA Chart

Fuse Medical Annual Data
Trend Aug13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.43 -0.83 -1.46 -1.95 0.68

Fuse Medical Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.62 2.96 0.17 -3.94 1.38

Competitive Comparison of Fuse Medical's Debt-to-EBITDA

For the Medical Devices subindustry, Fuse Medical's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fuse Medical's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Fuse Medical's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Fuse Medical's Debt-to-EBITDA falls into.



Fuse Medical Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Fuse Medical's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.147 + 0.2) / 3.43
=0.68

Fuse Medical's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.221 + 0) / 1.608
=1.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2023) EBITDA data.


Fuse Medical  (OTCPK:FZMD) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Fuse Medical Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Fuse Medical's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Fuse Medical (Fuse Medical) Business Description

Traded in Other Exchanges
N/A
Address
1565 N. Central Expressway, Suite 220, Richardson, TX, USA, 75080
Fuse Medical Inc is a manufacturer and distributor of medical devices. The company provides a comprehensive portfolio of products in the orthopedic total joints, sports medicine, trauma, foot and ankle space, as well as degenerative and deformity spine, orthobiologics, and regenerative medicine.
Executives
Lawrence Scott Yellin director, officer: Chief Financial Officer 5081 PINEVIEW CIRCLE, DELRAY BEACH FL 33445
Christopher C Reeg director, 10 percent owner, officer: Chief Executive Officer 3024 WESTMINSTER AVE, DALLAS TX 75205
Reeg Medical Industries, Inc. 10 percent owner 3024 WESTMINSTER AVE., DALLAS TX 75205
Mark W Brooks 10 percent owner 1565 NORTH CENTRAL EXPRESSWAY, SUITE 200, RICHARDSON TX 75080
Bosita Renato V. Jr. director TEXAS BACK INSTITUTE, 6020 WEST PARKER ROAD #200, PLANO TX 75025
Kalra Ricky Raj S. director 2513 SUNTREE LANE, PLANO TX 75025
Nc 143 Family Holdings, Lp 10 percent owner 1565 NORTH CENTRAL EXPRESSWAY, SUITE 200, RICHARDSON TX 75080
Medtech Family Trust 10 percent owner 1565 NORTH CENTRAL EXPRESSWAY, SUITE 200, RICHARDSON TX 75080
Mclaughlin William E Iii director 1565 NORTH CENTRAL EXPRESSWAY, 2ND FLOOR, RICHARDSON TX 75080
Nc 143 Family Holdings Gp Llc 10 percent owner 1565 NORTH CENTRAL EXPRESSWAY, SUITE 200, RICHARDSON TX 75080
Chris Pratt director, 10 percent owner, officer: Chief Medical Officer 4770 BRYANT IRVIN COURT, SUITE 300, FORT WORTH TX 76107
Randall Dei director, officer: Medical Director of Podiatry 4770 BRYANT IRVIN COURT, SUITE 300, FORT WORTH TX 76107
Rusty Shelton director, 10 percent owner, officer: Chief Development Officer 4770 BRYANT IRVIN COURT, SUITE 300, FORT WORTH TX 76107
David Hexter director, officer: Interim CFO 4770 BRYANT IRVIN COURT, SUITE 300, FORT WORTH TX 76107
D Alan Meeker director, 10 percent owner, officer: Chief Executive Officer 4770 BRYANT IRVIN COURT, SUITE 400, FORT WORTH TX 76107

Fuse Medical (Fuse Medical) Headlines

From GuruFocus